newsfilter
← Latest News
Business Wire·

Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update

– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol